Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 822
Filter
1.
Eur J Endocrinol ; 185(1): 121-135, 2021 05 25.
Article in English | MEDLINE | ID: mdl-33950863

ABSTRACT

Objective: The transcription factor OTX2 is implicated in ocular, craniofacial, and pituitary development. Design: We aimed to establish the contribution of OTX2 mutations in congenital hypopituitarism patients with/without eye abnormalities, study functional consequences, and establish OTX2 expression in the human brain, with a view to investigate the mechanism of action. Methods: We screened patients from the UK (n = 103), international centres (n = 24), and Brazil (n = 282); 145 were within the septo-optic dysplasia spectrum, and 264 had no eye phenotype. Transactivation ability of OTX2 variants was analysed in murine hypothalamic GT1-7 neurons. In situ hybridization was performed on human embryonic brain sections. Genetically engineered mice were generated with a series of C-terminal OTX2 variants. Results: Two chromosomal deletions and six haploinsufficient mutations were identified in individuals with eye abnormalities; an affected relative of one patient harboured the same mutation without an ocular phenotype. OTX2 truncations led to significant transactivation reduction. A missense variant was identified in another patient without eye abnormalities; however, studies revealed it was most likely not causative. In the mouse, truncations proximal to aa219 caused anophthalmia, while distal truncations and the missense variant were tolerated. During human embryogenesis, OTX2 was expressed in the posterior pituitary, retina, ear, thalamus, choroid plexus, and partially in the hypothalamus, but not in the anterior pituitary. Conclusions: OTX2 mutations are rarely associated with hypopituitarism in isolation without eye abnormalities, and may be variably penetrant, even within the same pedigree. Our data suggest that the endocrine phenotypes in patients with OTX2 mutations are of hypothalamic origin.


Subject(s)
Hypopituitarism/physiopathology , Microphthalmos/physiopathology , Neurons/physiology , Otx Transcription Factors/genetics , Pituitary Gland/physiopathology , Septo-Optic Dysplasia/physiopathology , Adolescent , Animals , Animals, Genetically Modified , Brazil , Cell Line , Child , Child, Preschool , Cohort Studies , Female , Humans , Hypopituitarism/embryology , Hypopituitarism/genetics , Hypothalamus/cytology , Infant , Male , Mice , Microphthalmos/embryology , Microphthalmos/genetics , Mutation , Neurons/pathology , Pedigree , Pituitary Gland/embryology , Pituitary Gland/pathology , Septo-Optic Dysplasia/embryology , Septo-Optic Dysplasia/genetics , United Kingdom
2.
World Neurosurg ; 149: e1043-e1055, 2021 05.
Article in English | MEDLINE | ID: mdl-33524611

ABSTRACT

OBJECTIVE: To present the outcomes of endoscopic endonasal surgery for giant pituitary adenomas and discuss the extent of resection to minimize morbidity and mortality. METHODS: We retrospectively reviewed medical records of 44 patients with giant pituitary adenomas who underwent endoscopic endonasal surgery. Clinical presentation, laboratory results, imaging studies, clinical outcomes, extent of resection, and complications were collected and analyzed. Factors affecting long-term outcome according to surgical technique were identified and analyzed. RESULTS: Radical resection (RR) was defined as either gross total resection or near-total resection (90%-100% of the tumor). There were 28 patients (63.6%) who underwent RR, 10 patients (22.7%) who underwent subtotal resection, and 6 patients (13.6%) who underwent partial resection. Visual improvement was achieved in 27 patients (81.8%). Thirteen patients (72.2%) with pituitary dysfunction had improvement in at least 1 preoperative endocrinological dysfunction. RR rates for dumbbell and multilobular tumors were 44.4% and 28.6%, respectively. Surgical complications were observed in 14 (31.8%) patients. Major vascular injury occurred in 3 patients (6.8%). Mean follow-up period was 38.5 months (range, 1-70 months). No patients with RR had recurrence or residual tumor progression. Ten patients (22.7%) received adjuvant radiation therapy after resection. Two patients were reoperated on for tumor regrowth, and 3 patients (including the 2 patients with tumor regrowth) were lost to follow-up. CONCLUSIONS: Long-term follow-up results and low recurrence rate of tumors indicate that RR is effective to decrease morbidity and mortality.


Subject(s)
Adenoma/surgery , Natural Orifice Endoscopic Surgery , Neuroendoscopy , Pituitary Neoplasms/surgery , Adenoma/pathology , Adenoma/physiopathology , Adolescent , Adult , Cerebrospinal Fluid Leak/epidemiology , Chemotherapy, Adjuvant , Cranial Nerve Diseases/physiopathology , Disease Progression , Female , Growth Hormone-Secreting Pituitary Adenoma/pathology , Growth Hormone-Secreting Pituitary Adenoma/physiopathology , Growth Hormone-Secreting Pituitary Adenoma/surgery , Humans , Hypopituitarism/physiopathology , Intraoperative Complications/epidemiology , Middle Aged , Nasal Cavity , Neoplasm Recurrence, Local , Neoplasm, Residual , Pituitary Neoplasms/pathology , Pituitary Neoplasms/physiopathology , Postoperative Complications/epidemiology , Prolactinoma/pathology , Prolactinoma/physiopathology , Prolactinoma/surgery , Radiotherapy, Adjuvant , Reoperation , Retrospective Studies , Treatment Outcome , Tumor Burden , Vascular System Injuries/epidemiology , Vision Disorders/physiopathology , Young Adult
3.
Mol Cell Endocrinol ; 525: 111173, 2021 04 05.
Article in English | MEDLINE | ID: mdl-33549603

ABSTRACT

The hypothalamus-pituitary-thyroid axis is one of several hormone regulatory systems from the hypothalamus to the pituitary and ultimately to the peripheral target organs. The hypothalamus and the pituitary gland are in close anatomical proximity at the base of the brain and extended through the pituitary stalk to the sella turcica. The pituitary stalk allows passage of stimulatory and inhibitory hormones and other signal molecules. The target organs are placed in the periphery and function through stimulation/inhibition by the circulating pituitary hormones. The several hypothalamus-pituitary-target organ axis systems interact in very sophisticated and complicated ways and for many of them the interactive and integrated mechanisms are still not quite clear. The diagnosis of central hypothyroidism is complicated by itself but challenged further by concomitant affection of other hypothalamus-pituitary-hormone axes, the dysfunction of which influences the diagnosis of central hypothyroidism. Treatment of both the central hypothyroidism and the other hypothalamus-pituitary axes also influence the function of the others by complex mechanisms involving both central and peripheral mechanisms. Clinicians managing patients with neuroendocrine disorders should become aware of the strong integrative influence from each hypothalamus-pituitary-hormone axis on the physiology and pathophysiology of central hypothyroidism. As an aid in this direction the present review summarizes and highlights the importance of the hypothalamus-pituitary-thyroid axis, pitfalls in diagnosing central hypothyroidism, diagnosing/testing central hypothyroidism in relation to panhypopituitarism, pointing at interactions of the thyroid function with other pituitary hormones, as well as local hypothalamic neurotransmitters and gut-brain hormones. Furthermore, the treatment effect of each axis on the regulation of the others is described. Finally, these complicating aspects require stringent diagnostic testing, particularly in clinical settings with lower or at least altered à priori likelihood of hypopituitarism than in former obvious clinical patient presentations.


Subject(s)
Hypothalamo-Hypophyseal System/physiopathology , Thyroid Gland/physiopathology , Animals , Hormones/blood , Hormones/metabolism , Humans , Hypopituitarism/blood , Hypopituitarism/pathology , Hypopituitarism/physiopathology , Hypothalamo-Hypophyseal System/pathology , Hypothyroidism/blood , Hypothyroidism/pathology , Hypothyroidism/physiopathology , Models, Biological , Thyroid Gland/pathology
4.
Ann Endocrinol (Paris) ; 82(3-4): 210-213, 2021 Jun.
Article in English | MEDLINE | ID: mdl-32473787

ABSTRACT

Besides its effects on longitudinal growth in childhood and its metabolic effects with consequences on body composition and lipid levels, growth hormone (GH) has important roles on maintaining the structure and function of the normal adult heart. GH/insulin like growth factor-I (IGF-I) also interacts with the vascular system and plays a role in the regulation of vascular tone. GH deficiency (GHD) in adulthood is associated with increased fat mass (particularly visceral) and abnormal lipid profile, which may contribute to the excess cardiovascular mortality observed in patients with panhypopituitarism. Treatment with GH improved body composition (by increasing lean mass and decreasing fat mass) and improved lipid profile. It also has beneficial effects on vascular walls. The improvement in cardiovascular morbidity and mortality induced by GH is less clear as data are scarce and obtained on small populations. The importance of alteration in cardiac morphology and function observed in GHD is debated, particularly when cardiac magnetic resonance is used rather than echocardiography. The effects of treatment with GH on heart function and morphology are modest when studied by echocardiography.


Subject(s)
Heart/drug effects , Human Growth Hormone/deficiency , Human Growth Hormone/pharmacology , Adult , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Cardiovascular Diseases/physiopathology , Cardiovascular System/drug effects , Cardiovascular System/physiopathology , Growth Disorders/complications , Growth Disorders/epidemiology , Growth Disorders/physiopathology , Heart/physiology , Human Growth Hormone/physiology , Humans , Hypopituitarism/complications , Hypopituitarism/epidemiology , Hypopituitarism/physiopathology , Morbidity , Risk Factors
5.
World Neurosurg ; 147: 172-180.e1, 2021 03.
Article in English | MEDLINE | ID: mdl-33346052

ABSTRACT

BACKGROUND: Data on neuroendocrine dysfunction (NED) in the acute setting of penetrating brain injury (PBI) are scarce, and the clinical approach to diagnosis and treatment remains extrapolated from the literature on blunt head trauma. METHODS: Three databases were searched (PubMed, Scopus, and Cochrane). Risk of bias was computed using the Newcastle-Ottawa Scale, or the methodological quality of case series and case reports, as indicated. This systematic review was registered in PROSPERO (42020172163). RESULTS: Six relevant studies involving 58 patients with PBI were included. Two studies were prospective cohort analyses, whereas 4 were case reports. The onset of NED was acute in all studies, by the first postinjury day. Risk factors for NED included worse injury severity and the presence of cerebral edema on imaging. Dysfunction of the anterior hypophysis involved the hypothalamic-pituitary-thyroid axis, treated with hormonal replacement, and hypocortisolism, treated with hydrocortisone. The prevalence of central diabetes insipidus was up to 41%. Most patients showed persistent NED months after injury. In separate reports, diabetes insipidus and hypocortisolism showed an association with higher mortality. The available literature for this review is poor, and the studies included had overall low quality with high risk of bias. CONCLUSIONS: NED seems to be prevalent in the acute phase of PBI, equally involving both anterior and posterior hypophysis. Despite a potential association between NED and mortality, data on the optimal management of NED are limited. This situation defines the need for prospective studies to better characterize the clinical features and optimal therapeutic interventions for NED in PBI.


Subject(s)
Adrenal Insufficiency/epidemiology , Brain Injuries/epidemiology , Diabetes Insipidus, Neurogenic/epidemiology , Head Injuries, Penetrating/epidemiology , Hypopituitarism/epidemiology , Hypothyroidism/epidemiology , Acute Disease , Adrenal Insufficiency/drug therapy , Adrenal Insufficiency/physiopathology , Brain Edema , Brain Injuries/physiopathology , Diabetes Insipidus, Neurogenic/drug therapy , Diabetes Insipidus, Neurogenic/physiopathology , Head Injuries, Closed/epidemiology , Head Injuries, Closed/physiopathology , Head Injuries, Penetrating/physiopathology , Humans , Hypopituitarism/drug therapy , Hypopituitarism/physiopathology , Hypothalamo-Hypophyseal System , Hypothyroidism/drug therapy , Hypothyroidism/physiopathology , Injury Severity Score , Mortality , Pituitary-Adrenal System , Prevalence , Prognosis , Thyroid Gland
6.
World Neurosurg ; 142: 593-600, 2020 10.
Article in English | MEDLINE | ID: mdl-32987615

ABSTRACT

Despite its benign histopathology, the treatment of craniopharyngioma remains one of the most formidable challenges faced by skull base surgeons. The technical challenges of tackling these complex central skull base lesions are paralleled by clinical challenges related to their unique tumor biology and the often-complex decision making required. In this article, we critically appraise the most recent literature to explore the challenges and controversies surrounding the management of these lesions. The role of curative resections and the shift in the surgical paradigm toward the multidisciplinary goal-directed management approach are discussed.


Subject(s)
Craniopharyngioma/surgery , Diabetes Insipidus/epidemiology , Hypopituitarism/epidemiology , Hypothalamic Diseases/epidemiology , Neurosurgical Procedures/methods , Obesity/epidemiology , Pituitary Neoplasms/surgery , Postoperative Complications/epidemiology , Craniopharyngioma/genetics , Craniopharyngioma/pathology , Craniopharyngioma/physiopathology , Diabetes Insipidus/therapy , Genomics , Hormone Replacement Therapy , Humans , Hypopituitarism/drug therapy , Hypopituitarism/physiopathology , Hypothalamic Diseases/complications , Molecular Targeted Therapy , Mortality , Neoplasm Recurrence, Local , Obesity/etiology , Patient Care Planning , Pituitary Neoplasms/genetics , Pituitary Neoplasms/pathology , Pituitary Neoplasms/physiopathology , Proto-Oncogene Proteins B-raf/genetics , Vision Disorders/physiopathology , beta Catenin/genetics
7.
World Neurosurg ; 142: 582-592, 2020 10.
Article in English | MEDLINE | ID: mdl-32987614

ABSTRACT

Surgery is the main treatment option for the management of craniopharyngiomas. Transcranial microsurgical approaches, such as pterional and subfrontal approaches, have constituted the classic operative strategy for resection of these tumors. However, the development of endoscopic endonasal approaches has revolutionized the treatment of craniopharyngiomas in the last 15 years, and endoscopic resection is favored for most craniopharyngiomas. In this article, we discuss our experience with the management of craniopharyngiomas and review the current results of the surgical treatment of those tumors, including discussion of goals of surgery, complications, recurrences, and the role of adjuvant treatment.


Subject(s)
Cerebrospinal Fluid Leak/epidemiology , Craniopharyngioma/surgery , Hypopituitarism/physiopathology , Natural Orifice Endoscopic Surgery/methods , Neuroendoscopy/methods , Pituitary Neoplasms/surgery , Postoperative Complications/epidemiology , Vision Disorders/physiopathology , Craniopharyngioma/diagnostic imaging , Craniopharyngioma/physiopathology , Humans , Hypopituitarism/epidemiology , Margins of Excision , Microsurgery , Nasal Cavity , Neoplasm Recurrence, Local , Pituitary Neoplasms/diagnostic imaging , Pituitary Neoplasms/physiopathology , Postoperative Cognitive Complications/epidemiology , Treatment Outcome
8.
BMJ Case Rep ; 13(9)2020 Sep 09.
Article in English | MEDLINE | ID: mdl-32912882

ABSTRACT

We report the case of a pituitary stalk germinoma initially misdiagnosed and treated as infundibuloneurohypophysitis (INH). A 27-year-old man presented with a 1-year history of polydipsia, polyuria, nycturia consistent with central diabetes insipidus and a hyperintense pituitary stalk lesion on MRI. A possible INH diagnosis was considered, after excluding other pathologies. Lesion biopsy was discarded at that time on the ground of a small target and the high risk of added morbidity. Oral desmopressin led to initial symptoms resolution but, in the following months, an anterior panhypopituitarism developed, in spite of appropriate treatment and, by that time, the brain MRI also revealed lesion growth, which prompted a biopsy recommendation. The pathology analysis revealed a germinoma. After chemotherapy and radiotherapy, there was complete disappearance of the pituitary lesion, but the panhypopituitarism persisted. In conclusion, this case highlights the importance and difficulty of precise diagnosis in the initial assessment of pituitary stalk lesions and the need for close monitoring of treatment response. Diagnostic reassessment and biopsy in atypical cases is the only path to achieve the correct diagnosis and treatment.


Subject(s)
Chemoradiotherapy/methods , Deamino Arginine Vasopressin/administration & dosage , Diabetes Insipidus, Neurogenic , Germinoma , Hydrocortisone/administration & dosage , Hypopituitarism , Pituitary Gland , Pituitary Neoplasms , Thyroxine/administration & dosage , Adult , Autoimmune Hypophysitis/diagnosis , Biopsy/methods , Diabetes Insipidus, Neurogenic/diagnosis , Diabetes Insipidus, Neurogenic/drug therapy , Diabetes Insipidus, Neurogenic/etiology , Diagnosis, Differential , Drug Monitoring/methods , Germinoma/pathology , Germinoma/physiopathology , Germinoma/therapy , Hormone Replacement Therapy/methods , Hormones/administration & dosage , Humans , Hypopituitarism/diagnosis , Hypopituitarism/etiology , Hypopituitarism/physiopathology , Magnetic Resonance Imaging/methods , Male , Pituitary Gland/diagnostic imaging , Pituitary Gland/pathology , Pituitary Neoplasms/pathology , Pituitary Neoplasms/physiopathology , Pituitary Neoplasms/therapy , Treatment Outcome
9.
BMC Endocr Disord ; 20(1): 84, 2020 Jun 09.
Article in English | MEDLINE | ID: mdl-32517690

ABSTRACT

BACKGROUND: Autoimmune hypophysitis is a rare disease characterized by the infiltration of lymphocytic cells into the pituitary gland. 18F-fluorodeoxyglucose (FDG) and 18F-2-fluorodeoxy sorbitol (FDS) positron emission tomography (PET) are well-established and emerging techniques, respectively, which may aid in the diagnosis and classification of autoimmune hypophysitis. CASE PRESENTATION: Here, we report a 40-year-old female diagnosed with central diabetes insipidus and multiple pituitary hormone deficiencies, and MRI revealed homogeneous signals in the pituitary gland as well as thickened in the pituitary stalk. FDG PET localized the pituitary and pituitary stalk lesions and displayed an SUVmax of 5.5. FDS, a sensitive radiotracer for bacterial infections but remains unproven under aseptic inflammation, also demonstrated elevated radioactivity, with an SUVmax of 1.1 at 30 min and 0.73 at 120 min. Transnasal biopsy suggested a diagnosis of autoimmune hypophysitis, and the patient displayed radiological and clinical improvement after treatment with glucocorticoids and hormone replacement. CONCLUSIONS: Autoimmune hypophysitis can display elevated FDG uptake, which aids in the localization of the lesions. In addition to revealing bacterial infection specifically, FDS can also accumulate under autoimmune conditions, suggesting that it could serve as a potential radiotracer for both bacterial and aseptic inflammation. TRIAL REGISTRATION: The patient was enrolled in study NCT02450942 (clinicaltrials.gov, Registered May 21, 2015).


Subject(s)
Autoimmune Hypophysitis/diagnostic imaging , Fluorodeoxyglucose F18 , Radiopharmaceuticals , Sorbitol/analogs & derivatives , Adult , Antidiuretic Agents/therapeutic use , Autoimmune Hypophysitis/drug therapy , Autoimmune Hypophysitis/pathology , Autoimmune Hypophysitis/physiopathology , Biopsy , Deamino Arginine Vasopressin/therapeutic use , Diabetes Insipidus, Neurogenic/drug therapy , Diabetes Insipidus, Neurogenic/physiopathology , Female , Glucocorticoids/therapeutic use , Hormone Replacement Therapy , Humans , Hypopituitarism/drug therapy , Hypopituitarism/physiopathology , Magnetic Resonance Imaging , Positron-Emission Tomography , Thyroxine/therapeutic use
10.
Pituitary ; 23(4): 400-408, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32415500

ABSTRACT

Twenty years after the first description of combined hypopituitarism (CPHD) caused by PROP1 mutations, the phenotype of affected subjects is still challenging for clinicians. These patients suffer from pituitary hormone deficits ranging from IGHD to panhypopituitarism. ACTH deficiency usually develops later in life. Pituitary size is variable. PROP1 mutation is the most frequent in familial congenital hypopituitarism (CH). Reports on initiation of hormonal replacement including growth hormone (GH) in adults with CH are scarce. We identified 5 adult siblings with CPHD due to PROP1 mutation (301-302delAG), aged 36-51 years (4 females), never treated for hormone deficiencies. They presented with short stature (SD from - 3.7 to - 4.7), infantile sexual characteristic, moderate abdominal obesity and low bone mineral density in 3 of them. Complete hypopituituitarism was confirmed in three siblings, while two remaining demonstrated GH, TSH, FSH and LH deficiencies. Required hormonal replacement including rhGH was initiated in all patients. After several months necessity for hydrocortisone replacement developed in all patients. After 2 years of continual replacement therapy, BMD and body composition (measured by DXA-dual X-ray absorptiometry) improved in all subjects, most prominently in two younger females and the male sibling. Besides rhGH therapy, these three patients have received sex hormones contributing to the favorable effect. The male sibling was diagnosed with brain glioblastoma two years following complete hormonal replacement. This report provides important experience regarding hormonal replacement, particularly rhGH treatment, in adults with long-term untreated CH. Beneficial effect of such therapy are widely acknowledged, yet these subjects could be susceptible to certain risks of hormonal treatment initiated in adulthood. Careful and continual clinical follow-up is thus strongly advised.


Subject(s)
Hormone Replacement Therapy , Hypopituitarism/drug therapy , Absorptiometry, Photon , Adult , Body Composition , Bone Density , Bone Diseases, Metabolic/diagnostic imaging , Bone Diseases, Metabolic/physiopathology , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/therapy , Disease Progression , Female , Glioblastoma/diagnostic imaging , Glioblastoma/therapy , Gonadal Steroid Hormones/therapeutic use , Growth Disorders/physiopathology , Homeodomain Proteins/genetics , Human Growth Hormone/therapeutic use , Humans , Hydrocortisone/therapeutic use , Hypopituitarism/metabolism , Hypopituitarism/physiopathology , Male , Middle Aged , Obesity, Abdominal/physiopathology , Phenotype , Quality of Life , Recombinant Proteins , Sexual Infantilism/physiopathology , Siblings , Testosterone/therapeutic use , Thyroxine/therapeutic use
12.
World Neurosurg ; 142: e1-e9, 2020 10.
Article in English | MEDLINE | ID: mdl-32217176

ABSTRACT

BACKGROUND: Rathke cleft cyst (RCC) can cause acute symptoms mimicking pituitary adenoma (PA) apoplexy. We evaluated the clinicoradiologic features for distinguishing RCC from PA apoplexy. METHODS: We retrospectively evaluated 22 patients with RCC and 24 patients with PA with apoplexy-like symptoms who underwent surgery via a transsphenoidal approach between November 1999 and December 2016. We compared the clinical data and magnetic resonance (MR) images between the 2 groups. RESULTS: The RCC group was younger and had smaller tumors compared with the PA group (P = 0.02 and 0.001, respectively). The incidences of visual deficits and cranial nerve palsy were lower in the RCCs than in the PAs (P ≤ 0.02 for all). MR images showed more frequent intracystic nodules in the RCCs (P < 0.001), whereas nodular enhancement and lateral deviation of the pituitary stalk were more commonly seen in the PAs (P ≤ 0.003 for both). However, the presence of endocrine dysfunction or decreased consciousness, and the recurrence ratio, were not significantly different between the groups (P ≥ 0.48 for all). In the multivariable logistic regression analysis, patients without nodular enhancement had a 15.84-fold greater risk of RCC than did those with nodular enhancement (P = 0.031). The probability of RCC decreased 0.59-fold with each 1-cm3 increase in tumor volume. CONCLUSIONS: RCC with apoplexy-like symptoms has different clinicoradiologic features compared with PA apoplexy. Patients with RCC present with milder ocular symptoms and smaller tumor volumes compared with those with PA apoplexy. The absence of nodular enhancement on MR images could suggest RCC.


Subject(s)
Adenoma/physiopathology , Central Nervous System Cysts/physiopathology , Pituitary Apoplexy/physiopathology , Pituitary Neoplasms/physiopathology , Adenoma/complications , Adenoma/diagnostic imaging , Adenoma/surgery , Adult , Case-Control Studies , Central Nervous System Cysts/diagnostic imaging , Central Nervous System Cysts/surgery , Consciousness Disorders/physiopathology , Cranial Nerve Diseases/physiopathology , Female , Headache/physiopathology , Humans , Hypopituitarism/physiopathology , Logistic Models , Magnetic Resonance Imaging , Male , Middle Aged , Multivariate Analysis , Nausea/physiopathology , Neurosurgical Procedures , Pituitary Apoplexy/diagnostic imaging , Pituitary Apoplexy/etiology , Pituitary Apoplexy/surgery , Pituitary Neoplasms/diagnostic imaging , Pituitary Neoplasms/surgery , Retrospective Studies , Vision Disorders/physiopathology , Vomiting/physiopathology , Young Adult
13.
Pituitary ; 23(4): 467-475, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32166618

ABSTRACT

BACKGROUND: It is still unclear whether growth hormone (GH) replacement is able to improve cardiovascular parameters in adults with GH deficiency (AGHD) from the updated clinical trials reported to date. METHODS AND RESULTS: We systematically reviewed clinical trials of GH treatment on AGHD patients in recent decade, and evaluated the effects of GH on cardiovascular parameters assessed by echocardiography. 11 clinical trials were identified in 3 bibliographic databases. We conducted a combined analysis of effects on four aspects: General indicators: baseline heart rate (BHR), peak heart rate (PHR), systolic blood pressure (SBP), diastolic blood pressure (DBP); Cardiac structure: left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), left ventricular interventricular septum (LVIS), left ventricular mass (LVM), left ventricular posterior wall (LVPW); Cardiovascular function: deceleration time of E wave (DT), E/A ratio (E/A), ejection fraction (EF), NT-BNP; Life quality: peak VO2, VE/VCO2 slope. Overall effect size was used to evaluate significance, and weighted mean difference after GH treatment was given to appreciate size of the effect. GH treatment was associated with a significant increase in BHR (3.03[2.00, 4.06]), LVIS (0.50[0.43, 0.57]), LVPW (0.50[0.43, 0.57]), and EF (2.12[1.34, 2.90]). Overall effect sizes were negative significant for DBP (- 1.19[- 2.33, - 0.05]), LVEDV (- 9.84[- 16.53, - 3.15]), NT-BNP (- 206.34[- 308.95, - 103.72]), and VE/VCO2 slope (- 2.31[- 2.92, - 1.71]). CONCLUSIONS: As assessed by echocardiography, GH administration may improve the general vital signs and life quality of AGHD patients, based on the positive effect on BHR and negative effects on DBP and VE/VCO2 slope. Also, GH treatment would influence the structure of heart with positive effects on LVIS, LVPW and negative effect on LVEDV, which together with the increase of EF and decrease of NT-BNP, then resulting in improving the systolic function of AGHD patients.


Subject(s)
Hormone Replacement Therapy , Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Hypopituitarism/drug therapy , Adult , Blood Pressure/physiology , Echocardiography , Heart Disease Risk Factors , Heart Rate/physiology , Heart Ventricles/diagnostic imaging , Heart Ventricles/pathology , Humans , Hypopituitarism/blood , Hypopituitarism/diagnostic imaging , Hypopituitarism/physiopathology , Natriuretic Peptide, Brain/blood , Organ Size , Oxygen Consumption/physiology , Peptide Fragments/blood , Recombinant Proteins , Stroke Volume/physiology , Ventricular Remodeling/physiology , Ventricular Septum/diagnostic imaging , Ventricular Septum/pathology
14.
Clin Neurol Neurosurg ; 192: 105711, 2020 05.
Article in English | MEDLINE | ID: mdl-32036264

ABSTRACT

OBJECTIVE: The optimal therapeutic approach to craniopharyngioma has not been established conclusively. The surgical outcome following radical excision and conservative resection with adjuvant radiotherapy are comparable or even better with the later in pediatric or mixed populations. This study is aimed at reviewing the role of extent of resection in local tumor control and long-term outcome in adults with craniopharyngioma. PATIENTS AND METHODS: Ninety-five adults operated between 2001 and 2013 were included. Progression-free survival (PFS) and overall survival (OS) were calculated. Predictors of various outcome parameters were analyzed. RESULTS: The predominant presenting symptom was visual impairment (78 %) followed by symptoms of hypothalamic involvement (29 %). Total and subtotal excisions (TE, STE) were achieved in 63 %, and 47 % of patients, respectively. Vision improved in 62 % of patients in the early postoperative period. Thirteen patients (14 %) experienced vision deterioration postoperatively. On multivariate analysis, tumor >3 cm and optic atrophy predicted poor visual outcome. Hormonal replacement for hypopituitarism was required in 83 % during follow-up. Diabetes insipidus was seen in 73 %. Imaging evidence of 3rd ventricular floor destruction by tumor emerged as an independent predictor of postoperative hypothalamic morbidities. The recurrence rate following TE and STE was 11.6 % and 72 %, respectively. Unlike radical excision, PFS following STE was significantly shorter (p- 0.02). TE was not associated with increased visual impairment or hypothalamic-pituitary dysfunction postoperatively as compared to STE. Most of the patients (85 %) were independent and able to return to the premorbid occupation. CONCLUSION: Subtotal resection provides equally good long-term visual, endocrinological, and hypothalamic outcomes as radical surgery. When used with adjuvant radiotherapy, it also gives a better local control of the tumor. Hence, subtotal resection with adjuvant radiotherapy should be considered as an effective alternative strategy to radical excision.


Subject(s)
Craniopharyngioma/surgery , Neoplasm Recurrence, Local/epidemiology , Neurosurgical Procedures/methods , Pituitary Neoplasms/surgery , Adrenal Insufficiency/metabolism , Adrenal Insufficiency/physiopathology , Adult , Craniopharyngioma/metabolism , Craniopharyngioma/physiopathology , Female , Functional Status , Growth Hormone/deficiency , Humans , Hypogonadism/metabolism , Hypogonadism/physiopathology , Hypopituitarism/metabolism , Hypopituitarism/physiopathology , Hypothyroidism/metabolism , Hypothyroidism/physiopathology , Male , Middle Aged , Neoplasm, Residual , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/physiopathology , Radiotherapy, Adjuvant , Treatment Outcome , Vision Disorders/physiopathology , Young Adult
15.
Clin Rheumatol ; 39(2): 595-606, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31446541

ABSTRACT

Granulomatosis with polyangiitis (GPA) is a necrotizing granulomatous vasculitis of small vessels that affect the pituitary gland in less than 1% of cases being exceptionally rare. To describe the clinical, biochemical, radiological findings, treatment, and outcomes of 4 patients with GPA-related hypophysitis. A systematic review of published cases with the same diagnosis is presented as well. A cross-sectional case series of patients with hypophysitis due to GPA from 1981 to 2018 at a third level specialty center. Literature review was performed searching in seven different digital databases for terms "granulomatosis with polyangiitis" and "pituitary gland" or "hypophysitis," including in the analysis all published cases between 1950 and 2019 with a minimum follow-up of 6 months. We found 197 patients with GPA in our institution of whom 4 patients (2.0%) had pituitary involvement. Clinical characteristics and outcomes are described. We also reviewed 7 case series, and 36 case reports describing pituitary dysfunction related to GPA from 1953 to 2019, including the clinical picture of an additional 74 patients. Pituitary dysfunction due to GPA is rare. Treatment is targeted to control systemic manifestations; nevertheless, the outcome of the pituitary function is poor. Central diabetes insipidus, particularly in younger women with other systemic features, should raise suspicion of GPA.Key Points• Involvement of the pituitary gland is an uncommon manifestation in GPA patients. The presence of central diabetes insipidus in the setting of systemic symptoms should prompt its suspicion.• In patients with pituitary involvement due to GPA, affection of other endocrine glands is rare, neither concomitant nor in different times during the disease course. This may arise the hypothesis of a local or regional pathogenesis affection of the gland.• There is no consensus on the best therapy strategy for GPA hypophysitis. Although the use of glucocorticoids with CYC is the most common drug combination, no differences in the outcome of the pituitary function and GPA disease course are seen with other immunosuppressants.• Poor prognosis regarding pituitary function is expected due to possible permanent pituitary tissue damage that results in the need of permanent hormonal replacement.


Subject(s)
Autoimmune Hypophysitis/physiopathology , Granulomatosis with Polyangiitis/physiopathology , Antidiuretic Agents/therapeutic use , Autoimmune Hypophysitis/diagnostic imaging , Autoimmune Hypophysitis/drug therapy , Autoimmune Hypophysitis/etiology , Deamino Arginine Vasopressin/therapeutic use , Diabetes Insipidus, Neurogenic/drug therapy , Diabetes Insipidus, Neurogenic/etiology , Diabetes Insipidus, Neurogenic/physiopathology , Female , Glucocorticoids/therapeutic use , Granulomatosis with Polyangiitis/complications , Granulomatosis with Polyangiitis/diagnostic imaging , Granulomatosis with Polyangiitis/drug therapy , Humans , Hyperprolactinemia/etiology , Hyperprolactinemia/physiopathology , Hypopituitarism/etiology , Hypopituitarism/physiopathology , Immunosuppressive Agents/therapeutic use , Magnetic Resonance Imaging , Male , Middle Aged
16.
Growth Horm IGF Res ; 50: 35-41, 2020 02.
Article in English | MEDLINE | ID: mdl-31862539

ABSTRACT

INTRODUCTION: Combined pituitary hormone deficiency (CPHD) can cause a broad spectrum of health problems, ranging from short stature only, to convulsions or even death. In the majority of patients, the cause is unknown. METHODS: The idex case had unexplained CPHD, pituitary anomalies on MRI and polydactyly. In the patients and her unaffected parents, we performed SNP array analysis and Whole Exome Sequencing, after candidate gene analysis turned out negative. RESULTS: We found a unique de novo heterozygous 229.9 kb deletion in the index case on chr. 2q14.2. This deletion covered 12 out of the 13 coding exons of the GLI2 gene, a transcription factor involved in midline formation and previously associated with CPHD. As reported GLI2 deletions and mutations show a large phenotypic variability, we performed a genotype-phenotype analysis. This revealed that GLI2 missense mutations usually present with a 'ppp-only' phenotype (pituitary anomalies ± postaxial polydactyly without brain phenotype), whereas the 'ppp-plus' phenotype (with major brain malformations and/or intellectual disabilities) is more frequent in patients with larger deletions, and those with frameshift mutations/point mutations or splice variants resulting in a stop codon (p < .001). CONCLUSION: The present case shows that a deletion of the GLI2 gene only (not affecting any of the adjacent genes) causes pituitary anomalies without brain phenotype. This suggests that brain phenotype only occurs when additional genes adjacent to GLI2 are deleted, or when mutations result in truncated GLI2 mRNA/protein. However, due to the lack of functional data for many GLI2 mutations and based on the available information regarding variable penetrance, phenotype-genotype correlations need to be made with caution.


Subject(s)
Fingers/abnormalities , Gene Deletion , Hypopituitarism/genetics , Nuclear Proteins/genetics , Polydactyly/genetics , Toes/abnormalities , Zinc Finger Protein Gli2/genetics , Child, Preschool , Female , Genotype , Hormone Replacement Therapy , Humans , Hypopituitarism/diagnostic imaging , Hypopituitarism/drug therapy , Hypopituitarism/physiopathology , Phenotype , Pituitary Gland/abnormalities , Pituitary Gland/diagnostic imaging , Exome Sequencing
17.
BMC Endocr Disord ; 19(1): 137, 2019 Dec 11.
Article in English | MEDLINE | ID: mdl-31829163

ABSTRACT

BACKGROUND: Body posture may be disordered by vestibular dysfunction, neurological disorders, problems with the distribution of muscle tone, brain injuries, and other dysfunctions. Growth hormone deficiency (GHD) can lead to many disorders, particularly of the musculoskeletal system. During treatment with recombinant human growth hormone (rhGH), an increase in muscle mass and an improvement in bone structure can be observed in children suffering from hypopituitarism from GHD. METHODS: The study involved 33 children suffering from hypopituitarism with GHD (9 girls and 24 boys), aged 10-14 years old. Measurements of the magnitude of their anterior-posterior spinal curvatures were made using an inclinometer. The children were examined at the medianus of the sacrum bone, the Th12-L1 intervertebral area, and the C7-Th1 intervertebral area. In order to characterize the anterior-posterior curvature of the spine, the results were compared with the general norms reported by Saunders. Statistical calculations were carried out using the statistical package Statistica 10 PL. RESULTS: Lumbar lordosis angles were higher in the patients currently receiving growth hormone (GH) treatment than in those who had yet to receive it. There is a statistically significant positive correlation between the length of growth hormone treatment and the alpha angle. There are also statistically significant correlations between age at the beginning of growth hormone therapy and the angle of lordosis. Statistically significant correlations were also seen between age at the beginning of growth hormone therapy and the alpha angle. CONCLUSIONS: Although there may be changes in posture at the beginning of rhGH treatment, the sooner growth hormone therapy begins, the better the body posture. The longer the growth hormone treatment, the better the posture, as expressed by the alpha angle in the sagittal plane.


Subject(s)
Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Hypopituitarism/complications , Spinal Curvatures/physiopathology , Adolescent , Age Factors , Child , Female , Humans , Hypopituitarism/physiopathology , Lordosis/etiology , Lordosis/physiopathology , Lumbar Vertebrae/physiopathology , Male , Posture , Spinal Curvatures/etiology , Time Factors
18.
Iran J Kidney Dis ; 13(6): 417-418, 2019 11.
Article in English | MEDLINE | ID: mdl-31880589

ABSTRACT

Sheehan syndrome (SS) is postpartum hypopituitarism resulting from pituitary gland necrosis caused by severe hypotension due to massive intra or post-partum hemorrhage. Defective NaCl transport in the distal convoluted tubule, due to mutations affecting the thiazide sensitive Na-Cl-cotransporter results in the autosomal recessive salt-losing renal tubulopathy, Gitelman syndrome (GS). These two have been rarely described together. We report the case of a middle-aged woman with both these conditions, resulting in management issues. Physicians encountering unexplained hypokalemia refractory to standard management must consider the possibility of renal tubular disorders.


Subject(s)
Gitelman Syndrome/diagnosis , Hypokalemia/etiology , Hypopituitarism/diagnosis , Adult , Comorbidity , Diagnosis, Differential , Female , Gitelman Syndrome/physiopathology , Humans , Hypopituitarism/physiopathology
20.
Childs Nerv Syst ; 35(11): 2133-2145, 2019 11.
Article in English | MEDLINE | ID: mdl-31385085

ABSTRACT

BACKGROUND: Craniopharyngioma has historically been recognized to be a formidable pathology primarily due to its proximity to critical neurovascular structures and the challenging surgical corridors that surgeons have tried to reach this lesion. FOCUS OF REVIEW: In this work, we review the medical and surgical management of these tumors with a focus on clinical presentation, diagnostic identification, surgical approach, and associated adjuvant therapies. We will also discuss our current treatment paradigm using endoscopic, open, and combined approaches to craniopharyngiomas. The management of craniopharyngiomas requires a multidisciplinary team of surgeons, endocrinologists, and neuroanesthesiologists as well as neurocritical care specialists to deliver the most comprehensive and safest surgical resection with minimal postoperative morbidity.


Subject(s)
Craniopharyngioma/surgery , Neuroendoscopy/methods , Pituitary Neoplasms/surgery , Adolescent , Child , Child, Preschool , Craniopharyngioma/diagnostic imaging , Craniopharyngioma/pathology , Craniopharyngioma/physiopathology , Hemianopsia/physiopathology , Humans , Hypopituitarism/physiopathology , Magnetic Resonance Imaging , Neurosurgical Procedures/methods , Pituitary Neoplasms/diagnostic imaging , Pituitary Neoplasms/pathology , Pituitary Neoplasms/physiopathology , Postoperative Complications/epidemiology , Radiotherapy, Adjuvant , Tomography, X-Ray Computed , Vision Disorders/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...